Pitcairn’s Maravai LifeSciences MRVI Stock Holding History

Pitcairn’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,624	Closed	-$83.2K	–	736
2024 Q2	$83.2K	Buy	+11,624	New	+$100K	0.01%	707

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Pitcairn's MRVI Position: Q3 2024 in Review

Pitcairn sold out of Maravai LifeSciences (MRVI) in Q3 2024, closing a stake of 11,624 shares — an estimated $83.2K sold.

Pitcairn first reported a position in MRVI in Q2 2024 and held it in 1 quarter. The position peaked at $83.2K in Q2 2024. 217 funds tracked by Wall St. Rank hold MRVI as of Q3 2024.

Pitcairn reported no remaining Maravai LifeSciences position as of Q3 2024 after selling out during the quarter.
Pitcairn sold 11,624 Maravai LifeSciences shares in Q3 2024, an estimated $83.2K.
Pitcairn first reported a position in Maravai LifeSciences in Q2 2024 and held it in 1 quarter.
Pitcairn's Maravai LifeSciences position peaked at $83.2K in Q2 2024.
217 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2024.

Based on Pitcairn's 13F filing for Q3 2024, filed 12 Nov 2024.